--- title: "Tango Therapeutics Inc. Metrics Guide" description: "Tango Therapeutics Inc. revenue, margins, cash flow and balance sheet figures by fiscal year, taken from its SEC filings, with the ratios explained." canonical: https://www.getswoopr.com/stocks/companies/tango-therapeutics-inc/financial-metrics/ source: "Swoopr Investment: https://www.getswoopr.com" --- # Tango Therapeutics Inc. Financial Metrics Guide ## Direct Answer > Tango Therapeutics Inc. reported revenue of $62 million for the fiscal year ended December 31, 2025, with an operating margin of -178.4% and net income of -$102 million, according to its SEC filings. Revenue grew 48.3% from the prior year. ## What Are Tango Therapeutics Inc.'s Key Financial Figures? | Fiscal year | FY2025ended December 31, 2025 | FY2024ended December 31, 2024 | FY2023ended December 31, 2023 | FY2022ended December 31, 2022 | | --- | --- | --- | --- | --- | | Revenue | $62 million | $42 million | $37 million | $25 million | | Operating income | -$111 million | -$146 million | -$114 million | -$111 million | | Operating margin | -178.4% | -346.1% | -312.6% | -446.8% | | Net income | -$102 million | -$130 million | -$102 million | -$108 million | | Net margin | -162.9% | -309.7% | -278.4% | -435.1% | | Operating cash flow | -$139 million | -$132 million | -$118 million | -$109 million | | Capital expenditures | $1 million | $754,000 | $2 million | $8 million | | Free cash flow | -$140 million | -$132 million | -$120 million | -$117 million | Operating margin widened by 167.7 percentage points between fiscal 2024 and 2025, which separates pricing and cost discipline from revenue growth alone. Free cash flow (operating cash flow minus capital expenditures) was -$140 million against net income of -$102 million; cash generation fell short of reported earnings, which is worth reconciling in the cash flow statement. ![Bar chart of Tango Therapeutics Inc. revenue, operating income, net income for fiscal 2022 to 2025. In fiscal 2025, revenue was $62 million, operating income negative $111 million and net income negative $102 million.](https://www.getswoopr.com/images/charts/tango-therapeutics-inc-metrics-revenue-profit.webp) *Tango Therapeutics Inc. revenue, operating income and net income by fiscal year, from the figures in the table above. Select the chart to open it full size.* ![Line chart of Tango Therapeutics Inc. operating margin and net margin for fiscal 2022 to 2025. In fiscal 2025, operating margin was -178.4% and net margin was -162.9%.](https://www.getswoopr.com/images/charts/tango-therapeutics-inc-metrics-margins.webp) *Tango Therapeutics Inc. operating margin and net margin by fiscal year: operating income and net income as a share of revenue. Select the chart to open it full size.* ![Bar chart of Tango Therapeutics Inc. operating cash flow, capital expenditures, free cash flow for fiscal 2022 to 2025. In fiscal 2025, operating cash flow was negative $139 million, capital expenditures was $1 million, free cash flow was negative $140 million.](https://www.getswoopr.com/images/charts/tango-therapeutics-inc-metrics-cash-flow.webp) *Tango Therapeutics Inc. operating cash flow, capital expenditures and free cash flow by fiscal year. Select the chart to open it full size.* ## What Does Tango Therapeutics Inc.'s Balance Sheet Show? | Cash and cash equivalents | $112 million | | --- | --- | | Long-term debt | Not reported | | Total assets | $399 million | | Total liabilities | $53 million | | Shareholders' equity | $346 million | | Current ratio | 16.3x | Balance sheet values are as of the end of fiscal 2025. Income statement figures describe a whole year; balance sheet figures describe a single day, so the two answer different questions. ## Where These Numbers Come From Every figure on this page is a value Tango Therapeutics Inc. reported in its own SEC filings, read from the SEC's XBRL data (accession 0001193125-26-092518 for fiscal year 2025). Ratios are computed from those reported values. Figures were retrieved on October 7, 2026; a later amendment or a new annual report can change them, and the filing itself always takes precedence over this summary. Each fiscal year is labeled by the calendar year in which it ended, so a company that names the same period differently in its own filings (many retailers whose year ends in January) may use another label. A year is left out of the table when the SEC data set holds no value for it. A figure shown as "Not reported" means the company did not file a value under the standard tag Swoopr reads, not that the amount was zero. This page is educational and describes reported history only; it is not a forecast or a recommendation. ## Frequently Asked Questions ### What was Tango Therapeutics Inc.'s revenue in fiscal 2025? Tango Therapeutics Inc. reported revenue of $62 million for the fiscal year ended December 31, 2025, according to its SEC filings. ### What is Tango Therapeutics Inc.'s operating margin? Tango Therapeutics Inc.'s operating margin was -178.4% in fiscal 2025: operating income of -$111 million on revenue of $62 million. ### How much free cash flow did Tango Therapeutics Inc. generate? Operating cash flow of -$139 million less capital expenditures of $1 million gives free cash flow of -$140 million for fiscal 2025. ## References - [SEC EDGAR: Tango Therapeutics, Inc. Form 10-K filed March 5, 2026](https://www.sec.gov/Archives/edgar/data/1819133/000119312526092518/tngx-20251231.htm) - [SEC EDGAR: Tango Therapeutics, Inc. annual and quarterly filings](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1819133&type=10-K) - [SEC: EDGAR application programming interfaces (XBRL frames and submissions data)](https://www.sec.gov/search-filings/edgar-application-programming-interfaces) ## Related Pages - [Tango Therapeutics Inc. company dossier](https://www.getswoopr.com/stocks/companies/tango-therapeutics-inc/) - [Tango Therapeutics Inc. financial metrics](https://www.getswoopr.com/stocks/companies/tango-therapeutics-inc/financial-metrics/) - [Tango Therapeutics Inc. financial risk indicators](https://www.getswoopr.com/stocks/companies/tango-therapeutics-inc/risks-monitoring/) - [Tango Therapeutics Inc. business model and revenue mix](https://www.getswoopr.com/stocks/companies/tango-therapeutics-inc/business-model/) - [Fundamental analysis guides](https://www.getswoopr.com/learn/fundamental-analysis/) [Swoopr Editorial Team](https://www.getswoopr.com/authors/swoopr-editorial-team/) Swoopr's editorial team produces independent investment education content. Content is for educational purposes only and does not constitute personalized investment advice. See our [editorial policy](https://www.getswoopr.com/legal/editorial-policy/) and [corrections policy](https://www.getswoopr.com/legal/corrections-policy/).